Repository logo
Communities
Research Outputs
Projects
Researchers
Statistics
  1. Home
  2. CRIS
  3. Publications
  4. Protective Role of Selenium-Binding Protein 1 (SELENBP1) in Patients with Ulcerative Colitis
Details

Protective Role of Selenium-Binding Protein 1 (SELENBP1) in Patients with Ulcerative Colitis

Journal
Metabolites
ISSN
2218-1989
Publisher
MDPI
Date Issued
2024
Author(s)
Fonseca-Camarillo, Gabriela
Furuzawa-Carballeda, Janette
Priego-Ranero, Ángel A.
Barreto-Zúñiga, Rafael
Martínez-Benítez, Braulio
Yamamoto-Furusho, Jesús K.
Type
Resource Types::text::journal::journal article
DOI
10.3390/metabo14120662
URL
https://scripta.up.edu.mx/handle/20.500.12552/11795
Abstract
Background: The expression of selenium-binding protein 1 (SELENBP1), a molecule responsible for the absorption of selenium in the colon, is crucial for its immunoregulatory effect, but this phenomenon has not been studied in patients with UC. The present study aimed to determine the clinical outcome of SELENBP1 expression in colonic tissue from patients with UC. Methods: The relative mRNA expression of SELENBP1 was analyzed in 34 patients with UC and 20 controls. Statistical analyses were performed with SPSS 19. Results: SELENBP1 gene expression was significantly lower in patients with active UC than those with UC in remission (p = 0.003) and within the controls (p = 0.04). Overexpression of the SELENBP1 gene was associated with a more benign clinical course characterized by initial activity and more than two years of prolonged remission (OR 23.7, p = 0.003) and an intermittent clinical course (OR 47.5, p = 0.001), mild histological activity (OR 0.11; 95% CI: 1.00–1.41, p = 0.05) and severe histological activity (OR 0.08, 95% CI: 0.008–0.866, p = 0.02). SELENBP1-positive cells were found mainly in the submucosa’s inflammatory infiltrate and muscular and adventitia’s internal layers from patients with active UC compared to those in the control group (p ≤ 0.001). Conclusions: The upregulation of SELENBP1 was associated with a benign clinical course of UC. This is the first report suggesting the immunoregulatory role of SELENBP1 in patients with UC. ©The authors ©MDPI
Subjects

Selenium

Selenbp1

Ulcerative colitis

Remission

Inmunoregulation

IBD

License
Acceso Abierto
URL License
https://creativecommons.org/licenses/by-nc-sa/4.0/
How to cite
Fonseca-Camarillo, G., Furuzawa-Carballeda, J., Priego-Ranero, Á. A., Barreto-Zúñiga, R., Martínez-Benítez, B., & Yamamoto-Furusho, J. K. (2024). Protective Role of Selenium-Binding Protein 1 (SELENBP1) in Patients with Ulcerative Colitis. In Metabolites (Vol. 14, Issue 12, p. 662). MDPI AG. https://doi.org/10.3390/metabo14120662

Envíanos tus dudas y solicitudes


Hosting & Support by

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Accessibility settings
  • Privacy policy
  • End User Agreement
  • Send Feedback
Repository logo COAR Notify